Meiji Holdings Co.,Ltd. FY2027 Q1 Earnings Report

Quick View

Executive Summary

Driven by improved profitability in the Pharmaceuticals segment and improved pricing and product mix in the Foods segment, the Company posted higher revenue and double-digit increases in operating income, ordinary income, and net income. Revenue was ¥2,894.0B (+5.8% YoY), operating income was ¥226.7B (+27.7%), ordinary income was ¥247.9B (+37.8%), and net income (consolidated net income for the period, including net income attributable to non-controlling interests) was ¥162.4B (+50.6%). Operating leverage emerged as the cost-of-sales ratio declined while the SG&A ratio remained broadly flat, resulting in an operating margin of 7.8%, improving from 6.5% in the previous year. Net income attributable to owners of the parent was ¥152.7B (+51.3%), while basic EPS was ¥56.33 (¥37.27 in the previous year).

Factors Affecting Performance

【Revenue】Revenue of ¥2,894.0B (+5.8% YoY) reflected higher revenue in both the Foods and Pharmaceuticals segments. Foods generated ¥2,339.4B (+4.1%), accounting for 80.8% of total revenue and remaining the core business, while Pharmaceuticals posted relatively strong growth of ¥556.9B (+13.6%).

【Profit and Loss】The gross margin improved to 30.7% from 29.2% in the previous year, indicating that pricing and product-mix effects exceeded the increase in the cost of sales. The SG&A ratio was broadly flat at 22.9%, allowing the improvement in gross margin to directly lift the operating margin. Operating income increased +27.7% to ¥226.7B. Non-operating income of ¥29.8B (including dividend income of ¥6.2B and foreign exchange gains of ¥7.5B) exceeded non-operating expenses of ¥8.6B, accelerating ordinary income growth to +37.8%, or ¥247.9B. Extraordinary income was ¥13.7B (including a gain on the sale of fixed assets of ¥6.4B), compared with extraordinary losses of ¥21.3B (including impairment losses of ¥11.0B), resulting in a small net loss of ▲¥7.6B; therefore, the impact of one-time factors on current-period earnings was limited. After deducting income taxes of ¥77.9B (effective tax rate of 32.4%) and net income attributable to non-controlling interests of ¥9.7B, net income attributable to owners of the parent was ¥152.7B (+51.3%). The key feature was that earnings growth significantly outpaced revenue growth amid higher revenue and higher profit.

Segment Analysis

The Foods segment generated revenue of ¥2,339.4B (+4.1% YoY) and operating income of ¥151.7B (+10.9%), with a modest improvement in its margin to 6.5% from 6.1% in the previous year. The Pharmaceuticals segment posted revenue of ¥556.9B (+13.6%) and substantial operating income growth of +76.3% to ¥84.4B, with its margin improving by 5.4pt to 15.2% from 9.8% in the previous year. Deducting the ¥9.3B adjustment for company-wide expenses and other items from total segment income of ¥236.1B reconciles to consolidated operating income of ¥226.7B. While Foods accounted for 80.8% of revenue, Pharmaceuticals drove profit growth, with the gap in segment margins widening to 8.7pt.

Key Financial Metrics

【Profitability】The operating margin improved by 1.3pt to 7.8% from 6.5% in the previous year, while the gross margin improved by 1.5pt to 30.7% from 29.2%. The consolidated net profit margin improved by 1.7pt to 5.6% from 3.9%, indicating consistent margin expansion from gross profit through to net income.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥147.2B, a significant improvement from ▲¥51.6B in the previous year. However, due to inventory build-up, actual OCF fell below the OCF subtotal before changes in working capital of ¥234.2B.【Investment Efficiency】ROE was 2.0% (quarterly result), calculated as net income attributable to owners of the parent of ¥152.7B divided by average equity during the period.【Financial Soundness】The Equity Ratio was 63.6%, slightly down from 64.8% in the previous year, while liquidity remained sound with a current ratio of 177.0%. The interest coverage ratio was 65.5x, calculated by dividing operating income of ¥226.7B by interest expense of ¥3.5B, indicating a limited interest burden. However, short-term borrowings increased +93.2% YoY to ¥411.8B, confirming an accumulation of short-term funding.

Cash Flow Analysis

OCF was ¥147.2B, a significant improvement from ▲¥51.6B in the previous year. This improvement was supported by securing an OCF subtotal before changes in working capital of ¥234.2B. However, the increase in inventories made a negative contribution of ▲¥199.6B to OCF, partially offsetting the positive effects of the decrease in trade receivables (+¥84.4B) and the increase in trade payables (+¥46.4B). Investing Cash Flow was ▲¥37.7B; despite capital expenditures of ¥148.2B, positive factors including the receipt of subsidies reduced the cash outflow from ▲¥144.2B in the previous year. Financing Cash Flow was positive at ¥105.6B, primarily due to an increase in short-term borrowings. Free cash flow (OCF + investing cash flow) was positive at ¥109.5B but fell short of dividend payments of ¥140.4B during the period, meaning that the shortfall was covered by external funding such as short-term borrowings. The increase in inventories is the key focus for future cash conversion, and whether inventories can be reduced will determine the quality of cash flow.

Quality of Earnings

Recurring earnings accounted for the vast majority of profit. Extraordinary items were modest at a net ▲¥7.6B (extraordinary income of ¥13.7B versus extraordinary losses of ¥21.3B) and did not materially distort the current-period earnings level. Non-operating income of ¥29.8B represented approximately 1.0% of revenue and primarily comprised recurring items such as dividend income, foreign exchange gains, and interest income. The difference between ordinary income of ¥247.9B and net income attributable to owners of the parent of ¥152.7B resulted from the deduction of income taxes of ¥77.9B and net income attributable to non-controlling interests of ¥9.7B and does not represent an abnormal divergence. Comprehensive income was ¥148.9B (¥139.8B attributable to owners of the parent), a difference of ▲¥13.5B from consolidated net income of ¥162.4B. This was due to a decrease of ▲¥21.5B in valuation differences on securities and a decrease of ▲¥7.7B in adjustments related to retirement benefits, which exceeded the positive foreign currency translation adjustment of +¥15.2B. OCF was approximately 0.96x net income, a generally sound level; however, the increase in inventories delayed cash conversion relative to earnings before changes in working capital, leaving room for improvement in cash flow quality.

Earnings Forecast and Guidance

The Q1 progress rates against the full-year plan were 23.9% for revenue (¥2,894.0B / ¥12,120.0B), 22.7% for operating income (¥226.7B / ¥1,000.0B), 24.5% for ordinary income (¥247.9B / ¥1,010.0B), and 24.4% for net income (attributable to owners of the parent). Compared with a simple one-fourth benchmark of 25%, operating income was progressing somewhat slowly (▲2.3pt), while ordinary income and net income were broadly at standard levels. Neither the earnings forecast nor the dividend forecast was revised during the quarter, and the full-year outlook remains based on the assumptions disclosed at the time of announcement. The somewhat slower progress in operating income is considered consistent with the business characteristic of sales being weighted toward the second half and the impact of inventory accumulation.

Shareholder Returns

The full-year dividend forecast is ¥110.00 per share, and the Payout Ratio based on forecast EPS of ¥230.61 is 47.7%. No share repurchase has been conducted or planned according to disclosed information, and the shareholder return policy is centered on dividends. Quarterly free cash flow of ¥109.5B was below dividend payments of ¥140.4B, meaning that funding during the period was supplemented by short-term borrowings and other sources. However, the adequacy of the annual dividend funding will depend on the full-year trend in OCF.

Risk Factors

1. Expansion of Working Capital: Inventories increased to ¥1,624.2B from ¥1,447.3B in the previous year, an increase of +¥176.9B (+12.2%), and represented a negative factor of ▲¥199.6B in OCF. Delays in reducing inventories could affect future cash conversion efficiency.

2. Greater Dependence on Short-Term Funding: Short-term borrowings increased +93.2% to ¥411.8B from ¥213.2B in the previous year. Greater dependence on short-term funding amid increased working capital requirements raises sensitivity to refinancing costs if interest rate conditions change.

3. Concentration in the Segment Earnings Structure: The Foods segment, which accounts for 80.8% of revenue, has a margin of only 6.5%, while the margin gap versus the Pharmaceuticals segment (15.2%) has widened to 8.7pt. The structure remains exposed to fluctuations in raw material and energy costs, which could affect the gross margin.

Industry Benchmark (Reference; Compiled by the Company)

Profitability and Returns

Both the operating margin and net profit margin exceed the industry median, indicating that profitability is relatively high within the Food and Beverage sector.

Growth and Capital Efficiency

The revenue growth rate is slightly above the industry median but has not reached the upper bound of the industry IQR (10.3%); growth therefore remains at a mid-range level.

※Source: Compiled by the Company

Key Takeaways from the Earnings Results

1. The Pharmaceuticals segment margin improved significantly from 9.8% in the previous year to 15.2%, creating a structural shift in which the segment drives company-wide profit growth despite accounting for 19.2% of revenue.

2. As the SG&A ratio remained broadly flat while the gross margin improved (+1.5pt), positive operating leverage emerged and the operating margin improved by +1.3pt. Margin improvement was supported by both cost-of-sales and expense management.

3. The increase in inventories constrained the cash conversion of OCF, and the gap between earnings growth and cash generation appeared in the form of increased short-term borrowings. The trend in inventory levels will be an important factor in assessing future cash flow quality.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly disclosed data using a residual income model (Ohlson-type model with an explicit 5-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥2,588–¥2,737 at a ±1% change in the cost of equity, and ¥2,654–¥2,665 at a change of ±0.1 in ω.

Notes:

• As forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the quarter-end are used (there is a timing difference relative to the full-year forecast).

(Calculation model: Residual income model / Interest rate reference month: 2026-07 / This value does not predict or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own responsibility and, where necessary, after consulting with a professional advisor.

---End of Report---